Abstract
Androgen deprivation therapy is a standard of care for metastatic
prostate cancer, however, eventually, all men relapse. A paradoxical
approach utilizing high doses of testosterone in castration-resistant
prostate cancer patients demonstrated clinical responses. Here we report
on four heavily pretreated CRPC patients successfully treated with
supra-physiological doses of testosterone.